BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) ...

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

Neutrolis Inc., a clinical stage biotech company focused on targeting Neutrophil Extracellular Traps (NETs) for the treatment of autoimmune and inflammatory diseases, ...

Jain, funded in part by grants from the National Eye Institute/NIH and Research to Prevent Blindness, established the feasibility of DNase therapies in moderate to severe DED and in ocular GvHD.

Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...

The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...

Post-COVID-19 condition (PCC) involves persistent symptoms like fatigue and cognitive dysfunction, affecting 8.4% of US adults. A randomized clinical trial showed cognitive and behavioral ...

FILE PHOTO: Signage is seen outside of FDA headquarters in White Oak, Maryland (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type ...

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called ...

The therapy, branded as Ryoncil, is the first mesenchymal stromal cell therapy approved to treat pediatric patients aged two months and older whose GVHD symptoms have not responded to standard ...